<code id='BD88253748'></code><style id='BD88253748'></style>
    • <acronym id='BD88253748'></acronym>
      <center id='BD88253748'><center id='BD88253748'><tfoot id='BD88253748'></tfoot></center><abbr id='BD88253748'><dir id='BD88253748'><tfoot id='BD88253748'></tfoot><noframes id='BD88253748'>

    • <optgroup id='BD88253748'><strike id='BD88253748'><sup id='BD88253748'></sup></strike><code id='BD88253748'></code></optgroup>
        1. <b id='BD88253748'><label id='BD88253748'><select id='BD88253748'><dt id='BD88253748'><span id='BD88253748'></span></dt></select></label></b><u id='BD88253748'></u>
          <i id='BD88253748'><strike id='BD88253748'><tt id='BD88253748'><pre id='BD88253748'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:9657
          Traffic on the Longfellow Bridge and the Kendall Square skyline are seen. -- health coverage from STAT
          Michael Dwyer/AP

          Around this time three years ago, while most of us navigated pandemic life, real estate developers across Greater Boston looked to life-science laboratories, and saw dollar signs.

          The white-collar office workers who’d long filled downtown towers were largely staying home (unless they worked in commercial real estate). The future of cities had rarely been murkier.

          advertisement

          But many biotech companies, like Cambridge’s Moderna, were busier than ever, and growing fast. Life-science companies, and the lab buildings that house them, looked like a sure bet for investors. Money poured in to drug companies by the billions — from venture capitalists, the stock market, the National Institutes of Health. And big real estate investors followed, launching a wave of speculative lab development all over Greater Boston.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Flagship Pioneering launches a new biotech in two countries
          Flagship Pioneering launches a new biotech in two countries

          AdobeFlagshipPioneering,theventurecapitalfirmbehindModerna,onTuesdayunveiledanewbiotechcalledQuotien

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          J&J to emphasize cancer drugs, stop much of its vaccine research

          DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm